Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
AKTX Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: June 14, 2026
Report Source: 2026 1st Quarter Report
Akari Therapeutics PLC. Stock Analysis AKTX
United States Health Care Nano Cap Report: Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. The company is headquartered in Tampa, Florida and currently employs 5 full-time employees. The company went IPO on 2014-01-31. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. The company is pursuing research on two additional novel payloads, such as PH5 and PH6. The company also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.
Read More Akari Therapeutics PLC (AKTX) Chart
Key Statistics of Akari Therapeutics PLC (AKTX)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$11.90Volume
60.28KP/E Ratio (TTM)
-52 Week Range
Market Cap
3.93MAvg. Volume
335.04KDividend Yield
-Financial Metrics & Statements of Akari Therapeutics PLC (AKTX)
FAQ's for Akari Therapeutics PLC (AKTX)
- According to Musaffa’s Shariah screening methodology, Akari Therapeutics PLC (AKTX) is currently classified as NOT HALAL as of June 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Akari Therapeutics PLC using these criteria to determine its compliance status.
- Muslim investors may consider investing in Akari Therapeutics PLC if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Akari Therapeutics PLC by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Akari Therapeutics PLC may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Akari Therapeutics PLC on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.